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Topical Treatment of Actinic Keratosis - New Ways of Treatment
E Stockfleth
University Department of Dermatology, Charite´ Hospital, Berlin, Germany
Actinic Keratosis (AK) is a squamous cell carcinoma of the epidermis in situ. There
are a number of treatment options currently available but not all are appropriate for
all patients or all lesions. AK lesions can be treated individually or, if the lesions are
numerous in an area of sun-damaged skin the whole area should be treated to
remove subclinical lesions as well as those clinically visible (field-directed
therapy). Polyphenons E is a defined extract from green tea leaves, containing a
mixture of green tea catechins. Developed for the topical treatment of HPV related
skin tumors with Genital Warts as first indication. We did the first promising phase
II study on actinic keratosis. Inhibitors of cyclo-oxygenase 2 (COX-2) inhibit
prostaglandin E2 (PGE2) that is known to suppress the production of immune-
regulatory lymphocytes, T-and B-cell proliferations and the cytotoxic activity of
natural killer cells. Cox-1/2 inhibitors like the combination between diclofenac and
hyaluronic acid work against AKs through inhibition of angiogenesis or through
induction of apoptosis. Recent Phase III clinical studies have highlighted that the
immune response modifier (IRM) imiquimod is effective in clearing both clinical
and subclinical AK lesions. In addition, initial results from three recently completed
studies of imiquimod: (1) a comparative study, (2) open label study with 829
patients and (3) a study in organ transplant recipients provides promising outcomes.
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Treatment of Merkel Cell Carcinoma
MM Delaunay
Skin and cancer Unit, Hoˆpital Saint Andre´, Bordeaux, France
Because of the relative rarity of the tumor, the treatment of Merkel cell carcinoma
(MCC) is not a matter of evidence based medicine. Despite the absence of large
series and randomized trials, the radioresponsiveness of the tumor and its
chemosensibility are well established. In stage I (primary tumour), surgery with
excision margins is performed. In clinical practice the margins depend on the size
and the site of the tumor. A two centimeters margin is recommended for tumours
larger than 1 cm. Mohs surgery allows to spare tissue and offers maximal security of
complete resection for tumors with an asymmetrical growth pattern. Most authors
recommend an additional 1 cm margin following the last positive section. Adjuvant
radiotherapy of the tumour site reduces the rate of local recurrence, as
demonstrated by retrospective series and by a meta-analysis of 11 series including
1024 cases. Because of the high rate of lymphatic metastases, an adjuvant therapy
concerning regional lymph nodes is often proposed. It consists in elective
lymphadenectomy (eventually followed by irradiation) or, more often, in irradiation
of the regional lymphatic area (50 GY). In France, a randomized trial has been
performed comparing surgery-radiotherapy of the primitive tumor to surgery-
radiotherapy associated with prophylactic irradiation of the regional nodes. The
trial was stopped after inclusion of 82 patients because of insufficient recruitment.
The intermediate analysis has demonstrated no regional recurrence in the irradiated
group. Complete results will be presented later. Sentinel node biopsy is now
proposed to determine microscopic node invasion. Positivity of the sentinel node
constitutes a strong prognostic factor. Selective lymph node dissection is performed
in case of positivity. The benefit of this attitude in comparison with prophylactic
irradiation remains to be determined. In stage II (nodes clinically detectable) radical
lymph node dissection and adjuvant irradiation are performed. In advanced cases,
neo adjuvant chemotherapy is proposed. In stage III (dissemination), a good
response rate is obtained with different protocols. Cyclophosphamide, Doxorubi-
cine or Epirubicine, Vincristine, Etoposide, Cis-platinum are the drugs most
frequently used, when possible in combination (CYC-ADR-VCR, VP16-CDDP). In a
meta analysis of 204 patients, the mean response rate is 75,6% (4). Despite of
chemosensitivity, median survival in stage III is only 9 months. In conclusion,
treatment of MCC is principally based on the association of surgery and
radiotherapy. The exact role of sentinel node procedure remains to be assessed.
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Graft Versus Host Disease and Extracorporeal Photochemotherapy. Reflection on
the Mechanism of Action
P Rubegni and M Fimiani
Dipartimento di Medicina Clinica e Scienze Immunologiche; Sez. Dermatologia-
Universita` di Siena, Italy
Chronic graft versus host disease (cGvHD) affects 50% of long-term marrow
transplant survivors and remains a cause of major long-term morbidity in these
patients despite aggressive therapy. Extracorporeal photochemotherapy (ECP),
considered as an effective treatment for patients with erythrodermic cutaneous T-
cell lymphoma, recently has been successfully used in the treatment of GvHD. It
consists on infusion of UVA irradiated autologous peripheral blood mononuclear
cells collected by apheresis and incubated with 8-methoxypsoralen. We report our
experience in 12 patients with chronic GvHD following non-myeloablative stem
cell transplantion for acute myeloid leukemia (n¼3), chronic myeloid leukemia
(n¼2), non-Hodgkin lymphoma (n¼ 2), acute lymphoblastic leukemia (n¼2),
multiple myeloma (n¼1), chronic lymphocytic leukemia (n¼2) and one case of
metastatic ovarian cancer. Besides peripheral blood mononuclear cell spontaneous
apoptosis, coexpression of CD4-CD25 phenotype and cytokine production before
and after ECP treatment was evaluated. In all treated patients, but in two, we
observed after therapy a partial or complete response of cutaneous, oral/ocular and
liver involvement. In all these cases it was possible to reduce or discontinue
immunosuppressive therapy. As regards programmed cell death, both annexin V
staining and measurement of DNA fragments showed that lymphocytes and
partially monocytes (about 50%) from the PUVA treated buffy coat bag undergo
enhanced spontaneous apoptosis in comparison with the other samples. Moreover
overexpression of CD4þCD25þ molecules was observed after ECP in 10 out of
12 treated patients after one year of treatment. In conclusion, ECP is effective as
either single or concomitant therapy in patients with chronic GvHD without
relevant side effects. Moreover in our study we demonstrated that lymphocytes
from the PUVA-treated bag undergo enhanced apoptosis in vitro. This accelerated
cell death together with overexpression of CD4-CD25 molecules may play a key
role in the not yet completely understood mechanism of action of ECP.
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Apoptosis and Skin Tumors
C Pincelli
Department of Dermatology, University of Modena and Reggio Emilia, Italy
Impaired ability to undergo programmed cell death in response to a wide range of
stimuli confers to cancers a selective advantage for progression and metastasis as
well as their strong resistance to therapy. UV radiation causes DNA damage,
followed by translocation of p53 to the nucleus with subsequent DNA repair or
apoptosis. Keratinocytes carrying p53 mutations may acquire resistance to
apoptosis. Thus, resistance to cell death is a key event in photocarcinogenesis.
Apoptosis-resistant keratinocytes undergo clonal expansion that eventually leads to
the formation of actinic keratoses and squamous cell carcinomas. Melanoma cells
are notoriously resistant to a variety of chemotherapeutic drugs by exploiting their
strong anti-apoptotic machinery or the alteration of molecules involved in the
regulation and execution of apoptosis. New strategies are in progress to bypass
these cell death defects through the modulation of pro-and antiapoptotic factors.
Preliminary work suggests that this strategy is very promising to find new ways of
treating cancer and to improve the actual poor prognosis of patients at late stages of
the disease.
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Pegylated Liposomal Doxorubicin (PLD) in the Treatment of Advanced Cutaneous
Lymphomas
M Cantonetti
Department of Hematology, Tor Vergata University, Rome, Italy
Primary cutaneous lymphomas (PCL) in the majority of histologic variants have an
indolent behaviour and a good prognosis with a prolonged survival. In a very small
subset of patients, PCL is aggressive at the onset and in patients who are resistant or
have relapsed after repeated traditional topic or systemic therapies, an advanced
disease is more frequently observed. In these patients the choice of the treatment is
not easy due to biologic and clinical heterogeneity of the disease and to cumulative
toxicity of previous therapies. The administration of the traditional systemic
(although aggressive) treatments results in a better initial response rate without
improving prognosis. Our experience confirms the efficacy and low toxicity of PLD
as single agent in second-line therapy of cutaneous T-Cell lymphoma as
demonstrated by Wollina U. et al. (Cancer 2003). We tested the safety and
efficacy of PLD in the treatment of 19 consecutive patients with advanced PCL (17
T-cell, 2 B-cell lymphomas), in association with three drugs of proven effectiveness
in nodal lymphoprolipherative and other primary cutaneous neoplastic disorders,
the CBVD therapy: PLD (Caelyxs) 12 mg/m2, Bleomycin 10 mg/m2, Vinblastine
6 mg/m2, Dacarbazine 375 mg/m2 at days 1 and 15, administered intravenously
every 4 weeks for 6 cycles. The overall response rate was 84.21% (Complete
Response 63.15%, Partial Response 21.05%, Progression of Disease 15.78%). The
CBVD therapy was well tolerated, only two patients presented neutrophil count
below 500/microliter, no patient had cardiac or mucosal toxicity, nor alopecia or
palmoplantar erytrodysesthesia.
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